Treatment of hepatitis patients in medical practice;Betreuung hepatitiskranker in der praxis

Medizinische Welt

Volumn 58, Issue 6, 2007, Pages 251-258

  Grungreiff K ^a  

^a NONE   (Germany)

Author keywords

Chronic liver disease; Hepatitis; Liver cirrhosis

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; BILE DUCT CARCINOMA; CHRONIC LIVER DISEASE; DISEASE COURSE; GASTROENTEROLOGY; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIFESTYLE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; REVIEW;

EID: 34547115442     PISSN: 00258512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Finestone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. Science 1973; 182: 1026.
2. Blumberg BS, Alter HJ, Visnich S. A new antigen in leukemia sera. JAMA 1965; 541-546.
3. Prince AM. An antigen detected in the blood during incubation period of serum hepatitis. Proc Natl Acad Sci 1968; 60: 814-821.
4. Choo QL et al. Isolation of a c-c-DNA derived from a blood born non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
5. Alter HJ et al. Detection of antibody to hepatitis C virus in prospectively transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321: 1494-1500.
6. Feinmann B, Berris B, Herst R. Anti-HCV in posttransfusion hepatitis: deductions from a prospective study. J Hepatol 1991; 12: 377-381.
7. Niederau C, Kapagiannidis C. Epidemiologie der chronischen Hepatitis C in Deutschland. Med Klin 2006; 101: 448-456.
8. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003; 38: S38-53.
9. Sola R et al. Probability of liver cancer and survival in HCV-related or alcoholic-decompensated cirrhosis. A study of 377 patients. Liver Intern 2006; 62-72.
10. Davis G et al. Projecting the future healthcare burden from hepatitis C in the United States. Hepatology 1998; 28: 390A.
11. Grüngreiff K. Die Leberzirrhose als Präkanzerose. Eine Analyse an einem unausgewählten ambulanten Patientengut. Verdauungskrankheiten 2003: 21: 129-134.
12. Keating G, Curran M. Peginterferon alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2003; 63: 701-730.
13. Scott LJ, Perry CM. Interferon alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002; 62: 507-556.
14. Marcellin P et al. Long-term histologic improvement and loss of detectable intrahepatic HCV-RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881.
15. Gockel HR, Heideman J, Lügering N. Viruspersistenz C. Lebenslange Infektion trotz Therapie? Med Klin 2006; 101: 378-383.
16. Radkowski M et al. Persistence of hepatitis C virus in patients successully treated for chronic hepatitis C. Hepatology 2005; 41: 106-114.
17. Pham TN et al. Hepatitis C virus persistence after spontaneous or treatment -induced resolution of hepatitis C. J Virol 2004; 78: 5867-5874.
18. Berg T. Hepatitis C : Rationale für die Therapie-Individualisierung. Hepatitis&more 2006; 1: 10-12.
19. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nature genetics 2002; 31: 339-343.
20. Caselmann WH et al. Leberzirrhose als Präkanzerose. Internist 1997; 38: 928-936.
21. Gluud C. Testosterone and alcoholic cirrhosis. Epidemiologic, pathophysiologic and therapeutic studies. Dan Med Bull 1988; 35: 564-575.
22. Nomura AM, Kolonel LN: Prostrate cancer: a current perspective. Epidemiol Rev 1991; 13: 200-237.
23. Sorensen HT et al. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 25: 921-925.
24. Anthony PP. Hepatocellular carcinoma : an overview. Histopathology 2001; 3: 109-118.
25. Grüngreiff K, Franke D, Kleine FD. Infektionen bei der Leberzirrhose als Auslöser des Coma hepaticum. Intensivmed 1991; 28: 188-195.
26. Pessione F et al. Cigarette smoking and hepatic lessions in patients with hepatitis C. Hepatology 2001; 34: 121-125.
27. Weitberg A, Corverse D. Oxygen radicals potentiate the genetic toxicity of tobacco specific nitrosamines. Clin Genet 1993; 43: 88-91.
28. Bosch FX et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
29. Greten TF et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer 2005; 92: 1862-1868.
30. Greten TF, Wedemeyer H, Manns MP. Prävention virusassoziierter Karzinomentstehung. Dt. Ärztebl 2006; 103: 1557-1563.
31. Hofmann WP et al. Effektivität der antiviralen Behandlung von Patienten mit chronischer Hepatitis C in der gastroenterologischen Praxis. Z Gastroenterol 2006; 44: 25-31.
32. Manns MP et al. Peginterferon-alfa-2b plus ribavirin compared with interferon-alfa2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.
33. Fried MW et al. Peginterferon-alfa2a plus ribavirin for chronic hepatitis virus infection. N Engl J Med 2002; 347: 975-982.
34. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Sem Liver Dis 2004; 24 (Suppl. 2): 25-31.
35. Berg T. Parardigmenwechsel bei chronischer Hepatitis C. Dt. Ärztezeitung 2006; 25: 38.
36. Volkmann X et al. Caspase activation is required for antiviral treatment response in chronic hepatitis C. Hepatology 2006; 43: 1311-1316.
37. Kondoh M et al. Activation of caspase-3 in HL-60 cells treated with pyrithione and zinc. Biol Pharm Bull 2005; 28: 757-759.
38. Grüngreiff K. Zink und Leber. 4. Auflage, 2006. Dr. Falk Pharma GmbH.
39. Sieja KS, Eversson GT. De novo hepatocellular carcinoma in a patient with hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy. Dig Dis Sci 2006; 51: 600-602.
40. Wasem J et al. Gesundheitsökonomische Aspekte chronischer Infektionskrankheiten am Beispiel der chronischen Hepatitis C. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2006; 49: 57-63.